Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.

Frontiers in Immunology is a leading open-access journal published by FRONTIERS MEDIA SA since 2010, dedicated to advancing knowledge in the field of immunology. With an impressive Q1 ranking in both Immunology and Allergy as of 2023, this journal exemplifies excellence in research dissemination, positioning itself among the top 22% of relevant literature in the discipline. The journal, based in Switzerland, emphasizes its commitment to open science by ensuring all published research is freely accessible, fostering collaboration and innovation among researchers, professionals, and students alike. With substantial visibility demonstrated by its ranks within the Scopus database—ranked #52 out of 233 in Immunology and Allergy, and #58 out of 236 in Immunology and Microbiology—Frontiers in Immunology serves as a vital platform for cutting-edge research. Researchers are invited to contribute original investigations and reviews that expand the understanding of immune mechanisms, therapeutic advancements, and clinical applications, making it a cornerstone for those looking to push the boundaries of immunological science.

INTERNATIONAL REVIEWS OF IMMUNOLOGY, published by Taylor & Francis Inc, is a leading academic journal that has been a cornerstone of immunological research since its inception in 1986. With an impressive impact factor and ranked in the top quartiles of its field (Q2 in both Immunology and Allergy), this journal offers a critical platform for the dissemination of influential findings and advancements within immunology. Spanning a diverse array of topics, from basic immune mechanisms to clinical applications, it aims to support the global scientific community in enhancing immunological understanding and therapeutic interventions. Researchers and professionals alike benefit from insights provided by renowned contributors, ensuring that the journal remains relevant in a rapidly evolving field. Directly accessible through subscription or institutional access, INTERNATIONAL REVIEWS OF IMMUNOLOGY is committed to fostering collaboration and innovation, making it an essential resource for anyone involved in immunological research and practice.

IMMUNOBIOLOGY is a prestigious academic journal published by Elsevier GmbH that significantly contributes to the fields of hematology and immunology. With its ISSN 0171-2985 and E-ISSN 1878-3279, this journal has been disseminating impactful research since 1979, positioning itself at the forefront of immunological and hematological advances. The journal holds a commendable ranking of Q2 in Hematology and Q3 in both Immunology and Immunology and Allergy, indicating its relevance and influence within the scientific community, as reflected by its Scopus rankings. Although IMMUNOBIOLOGY operates under a subscription model, it remains dedicated to expanding knowledge across disciplines, fostering innovative research, and facilitating connections among researchers, professionals, and students. Situated in Munich, Germany, this journal is continually evolving and aims to remain an essential resource for the latest discoveries and insights in the realms of immunity and blood disorders, ultimately enhancing our understanding of complex biological systems.

IMMUNOLOGY is a premier journal published by Wiley that has been at the forefront of the field since its inception in 1958. With an impressive impact factor and classified in the Q1 quartile for both Immunology and Allergy as of 2023, this journal is highly regarded among researchers and professionals alike. It ranks 36th out of 233 in the Medicine/Immunology and Allergy category, and 40th out of 236 in the Immunology and Microbiology segment on Scopus, placing it firmly within the top percentile of its field. The journal is dedicated to publishing high-quality research that advances our understanding of immunological processes, bridging basic science with clinical applications. Although it does not operate under an open-access model, it offers conventional access options that remain integral to the dissemination of vital immunological research. With its broad scope and commitment to scholarly excellence, IMMUNOLOGY continues to serve as an essential resource for those seeking the latest advancements in immunology, fostering innovation and collaboration among scientists globally.

PARASITE IMMUNOLOGY, published by Wiley, is a leading journal in the field of immunology and parasitology, with an ISSN of 0141-9838 and E-ISSN of 1365-3024. Since its inception in 1979, it has played a pivotal role in advancing our understanding of host-parasite interactions, immunological responses to parasitic infections, and the mechanisms of immunological resistance. The journal is adeptly positioned within the academic community, currently holding a prestigious Q2 ranking in Parasitology and a Q3 ranking in Immunology for 2023, indicating its significant influence and relevance. Its comprehensive scope attracts a diverse readership, contributing to the discourse surrounding novel therapeutic approaches and emerging challenges in parasitic diseases. With a consistent convergence of research until 2024, PARASITE IMMUNOLOGY is an essential resource for researchers, professionals, and students seeking to deepen their knowledge and foster collaboration in these dynamic fields. Although it is not an open-access journal, the insights shared within its pages are invaluable for shaping future research trajectories.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

Immunological Medicine, published by Taylor & Francis Ltd, is an esteemed open-access journal that has made significant strides in the field of immunology since its establishment in 2018. With an E-ISSN of 2578-5826, the journal has quickly gained recognition for its contribution to advancing immunological research, evidenced by its impressive ranking in the Q2 quartile for both immunology and allergy. Positioned in the United Kingdom, it offers a platform for publishing high-quality original research, reviews, and case studies that delve into the complex interactions of the immune system and its implications for human health. The journal serves as a vital resource for researchers, professionals, and students engaged in the burgeoning fields of immunology, providing open access to a wide audience and fostering collaboration and innovation. With a current Scopus ranking of #81 out of 233 in Immunology and Allergy and #97 out of 236 in Immunology and Microbiology, the journal aims to enhance the visibility and impact of cutting-edge research by bridging the gap between academia and clinical practice.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.